GlassScriptPhysician profile
Edmond M Young
NPI 1053424838
$11,761.93
in general payments reported to CMS, 2019-2025
37 companies · $1,681 in 2025
The $1,681 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $384 · 2021: $1,708 · 2022: $1,592 · 2023: $2,373 · 2024: $3,054 · 2025: $1,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,108.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,212.16 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,274.12 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $1,234.85 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tris Pharma INC | $756.80 | 2021-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Alkermes, INC. | $655.89 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $641.18 | 2019-2022 | |
| Corium, LLC | $519.32 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $492.50 | 2019-2025 | Spravato, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $414.21 | 2021-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $387.53 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $372.42 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $335.86 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $270.34 | 2021-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $269.01 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $223.45 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $202.86 | 2022-2024 | |
| Noven Therapeutics, LLC | $189.62 | 2023-2025 | Xelstrym |
| Lundbeck LLC | $186.93 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $156.99 | 2023-2025 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $145.85 | 2019-2023 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $139.25 | 2022-2025 | Aplenzin, Wellbutrin |
| Noven Pharmaceuticals, INC. | $119.30 | 2024 | Xelstrym |
| Indivior INC. | $98.66 | 2021-2024 | Perseris |
| Almatica Pharma LLC | $82.30 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Brainsway USA INC | $71.36 | 2025 | Deep Tms System |
| Shire North American Group INC | $40.41 | 2019 | |
| Jazz Pharmaceuticals INC. | $35.18 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $32.94 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $30.06 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $28.75 | 2021-2023 | Belsomra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.16 | 2025 | Rejoyn |
| Tempus Ai, INC | $22.72 | 2024 | |
| Sun Pharmaceutical Industries INC. | $19.96 | 2021 | |
| Biogen, INC. | $19.55 | 2024 | |
| Adlon Therapeutics L.P. | $18.16 | 2021 | |
| Alfasigma USA, INC. | $17.68 | 2022 | |
| Aytu Biopharma, INC. | $15.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmond Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.